Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Estimation of SARS-CoV-2 antibody prevalence through integration of serology and incidence data

View ORCID ProfileLiangliang Wang, Joosung Min, Renny Doig, View ORCID ProfileLloyd T Elliott, View ORCID ProfileCaroline Colijn
doi: https://doi.org/10.1101/2021.03.27.21254471
Liangliang Wang
1Department of Statistics and Actuarial Science Simon Fraser University, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Liangliang Wang
Joosung Min
1Department of Statistics and Actuarial Science Simon Fraser University, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renny Doig
1Department of Statistics and Actuarial Science Simon Fraser University, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lloyd T Elliott
1Department of Statistics and Actuarial Science Simon Fraser University, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lloyd T Elliott
Caroline Colijn
2Department of Mathematics Simon Fraser University, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Caroline Colijn
  • For correspondence: caroline_colijn@sfu.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Serology tests for SARS-CoV-2 provide a paradigm for estimating the number of individuals who have had infection in the past (including cases that are not detected by routine testing, which has varied over the course of the pandemic and between jurisdictions). Classical statistical approaches to such estimation do not incorporate case counts over time, and may be inaccurate due to uncertainty about the sensitivity and specificity of the serology test. In this work, we provide a joint Bayesian model for case counts and serological data, integrating uncertainty through priors on the sensitivity and specificity. We also model the Phases of the pandemic with exponential growth and decay. This model improves upon maximum likelihood estimates by conditioning on more data, and by taking into account the epidemiological trajectory. We apply our model to the greater Vancouver area, British Columbia, Canada with data acquired during Phase 1 of the pandemic.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The work was funded by Genome B.C.'s COVID-19 Rapid Response Funding Initiative (project code COV-142).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This work involves data that have been made publicly available by the British Columbia Centre for Disease Control, and so no IRB approval or exemption is required.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Open source software reproducing our experiments are provided on GitHub.

https://github.com/lell/serology

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted March 28, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Estimation of SARS-CoV-2 antibody prevalence through integration of serology and incidence data
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Estimation of SARS-CoV-2 antibody prevalence through integration of serology and incidence data
Liangliang Wang, Joosung Min, Renny Doig, Lloyd T Elliott, Caroline Colijn
medRxiv 2021.03.27.21254471; doi: https://doi.org/10.1101/2021.03.27.21254471
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Estimation of SARS-CoV-2 antibody prevalence through integration of serology and incidence data
Liangliang Wang, Joosung Min, Renny Doig, Lloyd T Elliott, Caroline Colijn
medRxiv 2021.03.27.21254471; doi: https://doi.org/10.1101/2021.03.27.21254471

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (157)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8542)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1741)
  • Geriatric Medicine (167)
  • Health Economics (371)
  • Health Informatics (1235)
  • Health Policy (618)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10274)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1668)
  • Nursing (97)
  • Nutrition (248)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (925)
  • Ophthalmology (263)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (111)
  • Palliative Medicine (40)
  • Pathology (252)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (207)
  • Psychiatry and Clinical Psychology (1760)
  • Public and Global Health (3831)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (318)
  • Respiratory Medicine (518)
  • Rheumatology (207)
  • Sexual and Reproductive Health (165)
  • Sports Medicine (157)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (100)
  • Urology (74)